A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene

Ribavirin for the Treatment of Lassa Fever: A Systematic Review and Meta-Analysis

(2019) Kirsten Alexandra Eberhardt et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

ICTV Virus Taxonomy Profile: Arenaviridae

(2019) Sheli R. Radoshitzky et al.   JOURNAL OF GENERAL VIROLOGY

A review of Lassa fever vaccine candidates

(2019) Kolawole Salami et al.   Current Opinion in Virology

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge

(2019) Maria S. Salvato et al.   Pathogens

Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot

(2019) Mathieu Mateo et al.   Science Translational Medicine

Mortality Among Confirmed Lassa Fever Cases During the 2015–2016 Outbreak in Nigeria

(2018) Maryam Ibrahim Buba et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

TIM-1 Mediates Dystroglycan-Independent Entry of Lassa Virus

(2018) Rachel B. Brouillette et al.   JOURNAL OF VIROLOGY

Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models

(2018) Penghui Li et al.   JOURNAL OF VIROLOGY

A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins

(2018) Xavier Carnec et al.   JOURNAL OF VIROLOGY

Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus)

(2018) David X Liu et al.   JOURNAL OF INFECTIOUS DISEASES

Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays

(2018) Yíngyún Caì et al.   Viruses-Basel

Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever

(2018) Tiago Abreu-Mota et al.   Nature Communications

Mutational Analysis of Lassa Virus Glycoprotein Highlights Regions Required for Alpha-Dystroglycan Utilization

(2017) Marissa Acciani et al.   JOURNAL OF VIROLOGY

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

(2017) Ana Maria Henao-Restrepo et al.   LANCET

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

(2017) Chad E Mire et al.   NATURE MEDICINE

Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein

(2017) Benson Y.H. Cheng et al.   VIROLOGY

DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs

(2017) Kathleen A. Cashman et al.   Human Vaccines & Immunotherapeutics

Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day

(2017) Natalie D. Collins et al.   Current Infectious Disease Reports

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

(2016) Robert W. Cross et al.   ANTIVIRAL RESEARCH

Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus

(2016) T. M. Bell et al.   VETERINARY PATHOLOGY

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

(2016) James E. Robinson et al.   Nature Communications

Synonymous Deoptimization of Foot-and-Mouth Disease Virus Causes AttenuationIn Vivowhile Inducing a Strong Neutralizing Antibody Response

(2015) Fayna Diaz-San Segundo et al.   JOURNAL OF VIROLOGY

Development of Live-Attenuated Arenavirus Vaccines Based on Codon Deoptimization

(2015) Benson Yee Hin Cheng et al.   JOURNAL OF VIROLOGY

Molecular Mechanism for LAMP1 Recognition by Lassa Virus

(2015) Hadas Cohen-Dvashi et al.   JOURNAL OF VIROLOGY

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

(2015) Ana Maria Henao-Restrepo et al.   LANCET

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

(2015) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

Mapping the zoonotic niche of Lassa fever in Africa

(2015) Adrian Q. N. Mylne et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset

(2015) David Safronetz et al.   Scientific Reports

Influenza A Virus Attenuation by Codon Deoptimization of the NS Gene for Vaccine Development

(2014) A. Nogales et al.   JOURNAL OF VIROLOGY

Lassa virus entry requires a trigger-induced receptor switch

(2014) L. T. Jae et al.   SCIENCE

Refining the Balance of Attenuation and Immunogenicity of Respiratory Syncytial Virus by Targeted Codon Deoptimization of Virulence Genes

(2014) J. Meng et al.   mBio

Lassa Fever in Post-Conflict Sierra Leone

(2014) Jeffrey G. Shaffer et al.   PLoS Neglected Tropical Diseases

Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice

(2013) Chen Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity

(2013) Juan C Zapata et al.   Virology Journal

Vaccines for viral hemorrhagic fevers—progress and shortcomings

(2013) Darryl Falzarano et al.   Current Opinion in Virology

Arenavirus Nucleoproteins Prevent Activation of Nuclear Factor Kappa B

(2012) W. W. S. I. Rodrigo et al.   JOURNAL OF VIROLOGY

Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity

(2012) N. Sogoba et al.   Zoonoses and Public Health

Immune Responses and Lassa Virus Infection

(2012) Marion Russier et al.   Viruses-Basel

The C-Terminal Region of Lymphocytic Choriomeningitis Virus Nucleoprotein Contains Distinct and Segregable Functional Domains Involved in NP-Z Interaction and Counteraction of the Type I Interferon Response

(2011) E. Ortiz-Riano et al.   JOURNAL OF VIROLOGY

Integrative genomics viewer

(2011) James T Robinson et al.   NATURE BIOTECHNOLOGY

Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression

(2011) K. M. Hastie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever

(2010) Daniel G. Bausch et al.   CLINICAL INFECTIOUS DISEASES

Use of Single-Cycle Infectious Lymphocytic Choriomeningitis Virus To Study Hemorrhagic Fever Arenaviruses

(2010) W. W. S. I. Rodrigo et al.   JOURNAL OF VIROLOGY

Live attenuated influenza virus vaccines by computer-aided rational design

(2010) Steffen Mueller et al.   NATURE BIOTECHNOLOGY

Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs

(2010) Xiaohong Jiang et al.   VACCINE

Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys

(2009) S. Baize et al.   JOURNAL OF VIROLOGY

Risk Maps of Lassa Fever in West Africa

(2009) Elisabeth Fichet-Calvet et al.   PLoS Neglected Tropical Diseases

Strain-specific antibody response to Lassa virus in the local population of west Africa

(2008) Petra Emmerich et al.   JOURNAL OF CLINICAL VIROLOGY

Virus Attenuation by Genome-Scale Changes in Codon Pair Bias

(2008) J. R. Coleman et al.   SCIENCE

Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates

(2008) Igor S. Lukashevich et al.   VACCINE